Aims: To summarize the current knowledge on the phenomenon of dogs, both trained and untrained, sensing hypoglycaemia and alerting their owners to it.
Methods: Electronic databases were searched for all types of articles reporting on untrained or trained 'diabetes alert' dogs. Articles published up until December 2014 in the English or German language were included.
Results: Several case reports and observational studies provide evidence that animals can perform at a level above that attributable to chance, and may reliably detect low diurnal as well as nocturnal hypoglycaemic episodes. Behavioural changes in untrained dogs were reported during 38-100% of hypoglycaemic events experienced by their owners. The sensitivity and specificity of the performance of trained diabetes alert dogs sensing hypoglycaemia ranged from 22 to 100% and 71 to 90%, respectively. Additionally, 75-81% of patients with diabetes who owned a trained dog reported a subsequent improvement in their quality of life. Nevertheless, the available data are limited and heterogeneous because they rely on low patient numbers and survey-based studies prone to recall bias.
Conclusion: Further research is needed to confirm the preliminary data on the reliability and mechanism underlying the dogs' abilities to detect hypoglycaemia, and its impact on patient outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dme.12975 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The rise of weekly insulins: addressing the challenges of type 2 diabetes care in Brazil.
Diabetol Metab Syndr
January 2025
Serviço de Endocrinologia (SEMPR) do Hospital das Clínicas da Universidade Federal do Paraná (UFPR), Curitiba, Brazil.
Background: Type 2 diabetes mellitus (T2D) is a global health concern with a rising prevalence, particularly in Brazil. Insulin therapy plays a crucial role in managing T2D, helping to maintain glucose and energy homeostasis. Moreover, early initiation of insulin is crucial for hyperglycemic control and prevention of chronic complications.
View Article and Find Full Text PDFBrain insulin resistance mediated cognitive impairment and neurodegeneration: Type-3 diabetes or Alzheimer's Disease.
Acta Neurol Belg
January 2025
Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, 124001, Haryana, India.
Insulin resistance is a condition characterized by the attenuated biological response in the presence of normal or elevated insulin level and therefore is characterized by the impaired sensitivity to insulin and impaired glucose disposal and utilization. Insulin resistance in brain/Brain insulin resistance (BIR) is accompanied by the various manifestations including alteration in glucose sensing by hypothalamic neurons, impaired sympathetic outflow in response to hypoglycemia, increased ROS production, impaired mitochondrial oxygen consumption in the brain, cognitive deficits and neuronal cell damage. It has been reported that the disrupted insulin signaling is accompanied by the reduced expression of insulin receptor (IR)/insulin receptor substrate 1 (IRS1)/PI3K/AKT and IGF-1 receptor (IGF-1R)/IRS2/PI3K pathways.
View Article and Find Full Text PDFTechniques for Implementing Continuous Glucose Monitoring in Primary Care: Key CGM Updates and Highlights from the EASD2024 Conference [Podcast].
Diabetes Metab Syndr Obes
November 2024
Division of Endocrinology, Metabolism, and Nutrition, Duke University School of Medicine, Durham, NC, USA.
This article discusses innovations, advancements, and discoveries in continuous glucose monitoring (CGM) that were presented at the European Association for the Study of Diabetes 2024 Conference in Madrid, Spain, held in September 2024. Specifically, the author will discuss data from studies that discuss the impact of CGM on hemoglobin A1C in people with type 2 diabetes; the impact of CGM use in hospitalization settings for people with diabetes; the effectiveness of CGM in those who have undergone cardiac surgery; the efficacy of real-time CGM in adults hospitalized with diabetic ketoacidosis; time in rage in older individuals; and new devices for glucose sensing.
View Article and Find Full Text PDFIntravenous glibenclamide for cerebral oedema after large hemispheric stroke (CHARM): a phase 3, double-blind, placebo-controlled, randomised trial.
Lancet Neurol
December 2024
Department of Neurology and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. Electronic address:
Article Synopsis
Explainable Machine-Learning Models to Predict Weekly Risk of Hyperglycemia, Hypoglycemia, and Glycemic Variability in Patients With Type 1 Diabetes Based on Continuous Glucose Monitoring.
J Diabetes Sci Technol
October 2024
Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.
Article Synopsis
- The study aimed to create and validate models that predict risks related to glucose levels (like high and low sugar levels) using continuous glucose monitoring (CGM) data to help patients and healthcare providers take preventive measures.
- Researchers analyzed data from 187 type 1 diabetes patients and developed three different prediction models, with XGBoost performing the best in accurately predicting hyperglycemia, hypoglycemia, and glycemic variability.
- The results showed that these models are effective in predicting risks for unstable glycemic control, demonstrating strong performance in both the original group and in external tests with additional patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!